Skip to main content
UniHealth

Doctor search

Stephanie A Christenson, MD

Pulmonary Disease · San Francisco

NPI 1528234937

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
2
Since medical school
20 years
Medical College of Wisconsin, 2006

Offices

2 locations · University of California San Francisco · Regents of the University of California

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Christenson’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A112221 · Current

Licensed to practise in California · since 2010 · expires 2028-05-31 · Medical College of Wisconsin.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Critical Care Medicine
  • American Board of Internal Medicine - Pulmonary Disease

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$14,188

Medicare paid this office $14,188 for 104 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Initial hospital care with moderate level of medical decision making at least 75 minutes25$3,842$154
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$2,951$105
Return visit (30+ min)33$2,866$82

Who their Medicare patients are

104 Original Medicare patients in 2024. Average age 74 · Women 59% · Also on Medicaid 39% · Health risk score 2.53. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.

Conditions among them: High blood pressure 75% · COPD 51% · Chronic kidney disease 41% · Heart failure 38% · Diabetes 35% · Cancer 34% · Coronary heart disease 31% · Depression 31% · Atrial fibrillation 23% · Stroke 17% · Dementia 11%.

The office billed $94,692, Medicare allowed $18,076 and paid $14,188; for 145 services of 14 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024104145742.53$94,692$14,188
2023118168732.59$127,381$17,541
2022122180732.30$169,824$22,220
2021100212712.09$222,543$30,243
202083215712.29$221,068$32,099
201985238703.47$200,962$28,910
2018109261692.57$171,593$27,354
2017111221702.58$143,851$24,145
201685185673.01$153,021$24,463
2015111289702.56$248,338$40,082
201485172692.03$126,056$20,482
20133442741.54$23,291$3,494

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Initial hospital care with moderate level of medical decision making at least 75 minutes35$5,507$157
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$2,914$108
New patient visit (45+ min)18$2,038$113
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$1,723$72
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,530$118
Return visit (30+ min)14$1,140$76

2022: 5 services

Original Medicare services billed in 2022
Critical care, first 30-74 minutes18$9,085$189
Initial hospital care with moderate level of medical decision making at least 75 minutes16$2,799$175
New patient visit (45+ min)21$2,401$114
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$2,360$91
Return visit (30+ min)20$1,691$70

2021: 5 services

Original Medicare services billed in 2021
Critical care, first 30-74 minutes43$20,480$193
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes16$1,939$92
New patient visit (45+ min)15$1,823$122
Return visit (30+ min)14$1,259$84
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$1,220$64

2020: 3 services

Original Medicare services billed in 2020
Critical care, first 30-74 minutes43$24,685$202
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$2,278$95
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes20$2,210$69

2019: 3 services

Original Medicare services billed in 2019
Critical care, first 30-74 minutes36$15,222$195
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$6,313$93
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes24$2,794$65

2018: 3 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes60$13,525$93
Critical care, first 30-74 minutes24$8,931$194
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes20$2,005$65

2017: 4 services

Original Medicare services billed in 2017
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes61$11,939$93
Critical care, first 30-74 minutes17$7,440$196
Long return visit (40+ min)13$1,391$99
Return visit (30+ min)16$985$62

2016: 2 services

Original Medicare services billed in 2016
Critical care, first 30-74 minutes31$14,600$195
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes45$7,286$92

2015: 3 services

Original Medicare services billed in 2015
Critical care, first 30-74 minutes44$26,436$197
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes46$7,670$94
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes24$2,215$65

2014: 4 services

Original Medicare services billed in 2014
Critical care, first 30-74 minutes33$11,083$194
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes27$3,648$91
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes32$2,798$65
Return visit (30+ min)15$983$66

2013: 1 service

Original Medicare services billed in 2013
Return visit (30+ min)13$906$65

Medicaid work

$5,875 in 2022

Medicaid paid $5,875 for 47 billed services this clinician did in 2022, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2022
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes47$5,875
Medicaid work by year
202247113$5,875

Drugs they prescribed that Part D paid

$97,573

Pharmacies billed $97,573 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 131) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.

46 generic and 85 brand-name prescriptions · $97,573 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Trelegy Ellipta13$13,173$1,013
Spiriva Respimat14$7,202$514
Symbicort15$3,292$219
Albuterol Sulfate Hfa16$520$33
Omeprazole13$135$10

Year by year

Part D prescribing by year
2024131310% (0)65%$97,573
202385240% (0)82%$32,742
202243160% (0)77%$19,056
202161170% (0)75%$23,695
202065140% (0)48%$19,311
2019105210% (0)69%$41,610
201879170% (0)97%$107,815
201791250% (0)80%$28,254
201647120% (0)53%$8,409
201548110% (0)65%$6,708
201456160% (0)82%$13,148
201346140% (0)83%$9,246

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Trelegy Ellipta17$11,703$688
Symbicort12$4,883$407
Ventolin Hfa12$1,044$87
Montelukast11$273$25

2022: 1 drug

Part D drugs prescribed in 2022
Trelegy Ellipta11$7,335$667

2021: 1 drug

Part D drugs prescribed in 2021
Stiolto Respimat12$5,163$430

2019: 4 drugs

Part D drugs prescribed in 2019
Spiriva Respimat22$10,071$458
Stiolto Respimat15$5,856$390
Advair Hfa11$5,604$509
Azithromycin14$305$22

2018: 2 drugs

Part D drugs prescribed in 2018
Spiriva Respimat27$11,552$428
Striverdi Respimat13$3,228$248

2017: 2 drugs

Part D drugs prescribed in 2017
Advair Diskus16$7,287$455
Advair Hfa12$5,627$469

2015: 3 drugs

Part D drugs prescribed in 2015
Advair Diskus11$4,231$385
Proair Hfa12$622$52
Fluticasone Propionate12$129$11

2014: 2 drugs

Part D drugs prescribed in 2014
Spiriva24$6,878$287
Advair Diskus12$4,298$358

2013: 1 drug

Part D drugs prescribed in 2013
Spiriva14$3,989$285

Money from drug and device companies

$91,791 in 2025

Industry payments by year
2025543$86,521$91,791
2024764$99,995$127,198
2023750$98,649$114,559
2022423$29,031$40,775
202139$14,364$14,364
2020417$58,355$58,717
2019453$29,214$44,753

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
GenzymeDupixent$58,168
14 payments
  • Consulting · 2025-11-24 · $10,127
  • Travel · 2025-11-11 · $614
  • Travel · 2025-11-11 · $924
  • Travel · 2025-11-11 · $274
  • Meals · 2025-11-11 · $134
  • Meals for Dupixent · 2025-09-17 · $126
  • Paid to speak or teach for Dupixent · 2025-09-17 · $9,025
  • Travel for Dupixent · 2025-09-17 · $705
  • Travel for Dupixent · 2025-09-17 · $469
  • Travel for Dupixent · 2025-09-17 · $381
  • Consulting · 2025-09-17 · $4,530
  • Paid to speak or teach for Dupixent · 2025-04-21 · $2,527
  • Paid to speak or teach for Dupixent · 2025-04-09 · $28,297
  • Meals for Wayrilz · 2025-02-06 · $35
AstraZeneca Pharmaceuticals LPFasenra$25,888
20 payments
  • Consulting · 2025-12-03 · $4,028
  • Consulting for Saphnelo · 2025-11-21 · $269
  • Consulting · 2025-10-10 · $2,148
  • Consulting for Breztri · 2025-09-22 · $2,148
  • Consulting · 2025-09-19 · $2,148
  • Consulting for Fasenra · 2025-09-18 · $4,833
  • Meals for Breztri · 2025-09-12 · $64
  • Meals for Breztri · 2025-09-12 · $55
  • Travel for Breztri · 2025-09-12 · $284
  • Meals for Breztri · 2025-09-12 · $20
  • Meals for Breztri · 2025-09-12 · $135
  • Meals for Breztri · 2025-09-12 · $20
  • Meals for Breztri · 2025-09-12 · $41
  • Travel for Breztri · 2025-09-12 · $58
  • Travel for Breztri · 2025-09-12 · $644
  • Consulting · 2025-09-05 · $5,639
  • Consulting · 2025-06-20 · $2,417
  • Meals · 2025-05-19 · $135
  • Consulting · 2025-03-06 · $537
  • Consulting · 2025-01-16 · $269
AstraZeneca UKFasenra$5,481
7 payments
  • Consulting · 2025-12-22 · $1,074
  • Consulting for Fasenra · 2025-11-17 · $1,837
  • Meals · 2025-09-27 · $46
  • Meals · 2025-09-27 · $17
  • Consulting · 2025-06-04 · $806
  • Meals for Breztri · 2025-05-17 · $90
  • Consulting · 2025-05-02 · $1,611
Verona PharmaOhtuvayre$1,500
1 payment
  • Consulting for Ohtuvayre · 2025-06-11 · $1,500
Sanofi US ServicesNone$755
1 payment
  • Consulting · 2025-11-07 · $755
See all 43 published payments
Every published payment
AstraZeneca UKConsulting · 2025-12-22None$1,074
AstraZeneca Pharmaceuticals LPConsulting · 2025-12-03None$4,028
GenzymeConsulting · 2025-11-24None$10,127
AstraZeneca Pharmaceuticals LPConsulting · 2025-11-21Saphnelo$269
AstraZeneca UKConsulting · 2025-11-17Fasenra$1,837
GenzymeTravel · 2025-11-11None$614
GenzymeTravel · 2025-11-11None$924
GenzymeTravel · 2025-11-11None$274
GenzymeMeals · 2025-11-11None$134
Sanofi US ServicesConsulting · 2025-11-07None$755
AstraZeneca Pharmaceuticals LPConsulting · 2025-10-10None$2,148
AstraZeneca UKMeals · 2025-09-27None$46
AstraZeneca UKMeals · 2025-09-27None$17
AstraZeneca Pharmaceuticals LPConsulting · 2025-09-22Breztri$2,148
AstraZeneca Pharmaceuticals LPConsulting · 2025-09-19None$2,148
AstraZeneca Pharmaceuticals LPConsulting · 2025-09-18Fasenra$4,833
GenzymeMeals · 2025-09-17Dupixent$126
GenzymePaid to speak or teach · 2025-09-17Dupixent$9,025
GenzymeTravel · 2025-09-17Dupixent$705
GenzymeTravel · 2025-09-17Dupixent$469
GenzymeTravel · 2025-09-17Dupixent$381
GenzymeConsulting · 2025-09-17None$4,530
AstraZeneca Pharmaceuticals LPMeals · 2025-09-12Breztri$64
AstraZeneca Pharmaceuticals LPMeals · 2025-09-12Breztri$55
AstraZeneca Pharmaceuticals LPTravel · 2025-09-12Breztri$284
AstraZeneca Pharmaceuticals LPMeals · 2025-09-12Breztri$20
AstraZeneca Pharmaceuticals LPMeals · 2025-09-12Breztri$135
AstraZeneca Pharmaceuticals LPMeals · 2025-09-12Breztri$20
AstraZeneca Pharmaceuticals LPMeals · 2025-09-12Breztri$41
AstraZeneca Pharmaceuticals LPTravel · 2025-09-12Breztri$58
AstraZeneca Pharmaceuticals LPTravel · 2025-09-12Breztri$644
AstraZeneca Pharmaceuticals LPConsulting · 2025-09-05None$5,639
AstraZeneca Pharmaceuticals LPConsulting · 2025-06-20None$2,417
Verona PharmaConsulting · 2025-06-11Ohtuvayre$1,500
AstraZeneca UKConsulting · 2025-06-04None$806
AstraZeneca Pharmaceuticals LPMeals · 2025-05-19None$135
AstraZeneca UKMeals · 2025-05-17Breztri$90
AstraZeneca UKConsulting · 2025-05-02None$1,611
GenzymePaid to speak or teach · 2025-04-21Dupixent$2,527
GenzymePaid to speak or teach · 2025-04-09Dupixent$28,297
AstraZeneca Pharmaceuticals LPConsulting · 2025-03-06None$537
GenzymeMeals · 2025-02-06Wayrilz$35
AstraZeneca Pharmaceuticals LPConsulting · 2025-01-16None$269
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $127,198

Payments by company in 2024
GenzymeDupixent$69,739
24 payments
  • Paid to speak or teach for Dupixent · 2024-12-03 · $2,643
  • Paid to speak or teach · 2024-12-02 · $2,718
  • Consulting · 2024-10-22 · $2,205
  • Paid to speak or teach · 2024-10-09 · $5,196
  • Consulting for Dupixent · 2024-09-26 · $5,432
  • Paid to speak or teach for Dupixent · 2024-07-29 · $2,643
  • Consulting for Dupixent · 2024-06-12 · $11,136
  • Meals for Dupixent · 2024-06-12 · $42
  • Meals for Dupixent · 2024-06-12 · $21
  • Travel for Dupixent · 2024-06-12 · $300
  • Travel for Dupixent · 2024-06-12 · $390
  • Travel for Dupixent · 2024-06-12 · $7,644
  • Paid to speak or teach for Dupixent · 2024-05-20 · $1,250
  • Paid to speak or teach · 2024-05-20 · $906
  • Paid to speak or teach for Dupixent · 2024-05-19 · $3,624
  • Paid to speak or teach for Dupixent · 2024-04-30 · $9,438
  • Travel · 2024-03-15 · $150
  • Travel · 2024-03-15 · $215
  • Meals · 2024-03-15 · $112
  • Meals · 2024-03-15 · $40
  • Meals · 2024-03-15 · $64
  • Meals · 2024-03-15 · $68
  • Consulting · 2024-03-15 · $12,835
  • Travel · 2024-03-15 · $665
AstraZeneca UKNone$26,376
21 payments
  • Consulting · 2024-12-10 · $3,759
  • Consulting · 2024-11-20 · $1,611
  • Travel · 2024-11-04 · $13,990
  • Travel · 2024-11-04 · $139
  • Meals · 2024-11-04 · $81
  • Meals · 2024-11-04 · $29
  • Travel · 2024-11-04 · $269
  • Meals · 2024-11-04 · $59
  • Travel · 2024-11-04 · $258
  • Travel · 2024-11-04 · $129
  • Travel · 2024-11-04 · $178
  • Meals · 2024-11-04 · $28
  • Travel · 2024-11-04 · $178
  • Meals · 2024-11-04 · $29
  • Meals · 2024-11-04 · $28
  • Consulting · 2024-10-15 · $3,222
  • Meals · 2024-09-11 · $29
  • Meals · 2024-09-11 · $29
  • Meals · 2024-09-11 · $47
  • Consulting · 2024-06-26 · $1,074
  • Consulting · 2024-03-11 · $1,208
AstraZeneca Pharmaceuticals LPNone$12,260
3 payments
  • Consulting · 2024-11-27 · $7,024
  • Consulting · 2024-11-25 · $3,625
  • Consulting · 2024-05-22 · $1,611
AmgenNone$9,491
9 payments
  • Consulting · 2024-06-07 · $5,256
  • Consulting · 2024-06-07 · $2,628
  • Meals · 2024-05-23 · $25
  • Meals · 2024-05-23 · $67
  • Travel · 2024-05-23 · $246
  • Meals · 2024-05-23 · $25
  • Travel · 2024-05-23 · $736
  • Meals · 2024-05-22 · $125
  • Travel · 2024-05-16 · $384
Genentech USANone$5,606
3 payments
  • Consulting · 2024-10-05 · $4,290
  • Meals · 2024-10-05 · $326
  • Consulting · 2024-08-28 · $990
Regeneron Healthcare SolutionsDupixent$3,698
3 payments
  • Paid to speak or teach · 2024-10-23 · $2,907
  • Meals for Dupixent · 2024-03-08 · $27
  • Paid to speak or teach · 2024-02-29 · $764
AstraZeneca ABNone$29
1 payment
  • Meals · 2024-09-06 · $29

2023: $114,559

Payments by company in 2023
GenzymeDupixent$65,897
15 payments
  • Consulting · 2023-12-09 · $14,874
  • Travel · 2023-12-09 · $321
  • Travel · 2023-12-09 · $10,709
  • Travel · 2023-12-09 · $424
  • Consulting for Dupixent · 2023-10-03 · $10,188
  • Paid to speak or teach · 2023-09-11 · $10,188
  • Consulting · 2023-09-11 · $4,923
  • Paid to speak or teach for Dupixent · 2023-09-09 · $250
  • Consulting · 2023-06-05 · $2,899
  • Paid to speak or teach for Dupixent · 2023-05-22 · $500
  • Meals · 2023-04-14 · $142
  • Travel · 2023-04-14 · $198
  • Travel · 2023-04-14 · $269
  • Travel · 2023-04-14 · $534
  • Consulting · 2023-04-14 · $9,477
Sanofi US ServicesDupixent$18,654
4 payments
  • Consulting for Dupixent · 2023-10-06 · $5,126
  • Consulting for Dupixent · 2023-05-18 · $12,222
  • Meals for Dupixent · 2023-05-18 · $402
  • Travel for Dupixent · 2023-05-18 · $904
AstraZeneca Pharmaceuticals LPAirsupra$11,729
14 payments
  • Consulting · 2023-09-05 · $7,250
  • Meals for Airsupra · 2023-07-22 · $50
  • Meals for Airsupra · 2023-07-22 · $79
  • Meals for Airsupra · 2023-07-21 · $60
  • Meals for Airsupra · 2023-07-21 · $135
  • Meals for Airsupra · 2023-07-21 · $50
  • Meals for Airsupra · 2023-07-21 · $48
  • Travel for Airsupra · 2023-07-21 · $260
  • Travel for Airsupra · 2023-07-20 · $517
  • Travel for Airsupra · 2023-07-20 · $260
  • Meals for Airsupra · 2023-07-20 · $135
  • Travel for Airsupra · 2023-07-20 · $202
  • Consulting · 2023-05-17 · $1,611
  • Consulting · 2023-01-19 · $1,074
GlaxoSmithKlineTrelegy Ellipta$7,800
1 payment
  • Consulting for Trelegy Ellipta · 2023-07-18 · $7,800
Regeneron PharmaceuticalsDupixent$6,413
5 payments
  • Consulting for Dupixent · 2023-08-11 · $1,040
  • Consulting for Dupixent · 2023-08-11 · $2,080
  • Consulting for Dupixent · 2023-08-11 · $3,120
  • Meals for Dupixent · 2023-05-19 · $118
  • Meals for Dupixent · 2023-05-19 · $55
AstraZeneca UKNone$3,260
5 payments
  • Consulting · 2023-11-21 · $1,880
  • Meals · 2023-09-12 · $38
  • Consulting · 2023-08-31 · $537
  • Consulting · 2023-05-30 · $537
  • Consulting · 2023-02-16 · $269
AstraZeneca ABNone$806
2 payments
  • Consulting · 2023-11-27 · $537
  • Consulting · 2023-07-21 · $269

2022: $40,775

Payments by company in 2022
GenzymeDupixent$23,964
7 payments
  • Meals for Dupixent · 2022-12-09 · $140
  • Meals for Dupixent · 2022-12-09 · $70
  • Travel for Dupixent · 2022-12-09 · $338
  • Travel for Dupixent · 2022-12-09 · $293
  • Consulting for Dupixent · 2022-12-09 · $8,398
  • Consulting for Dupixent · 2022-10-04 · $5,813
  • Consulting for Dupixent · 2022-09-03 · $8,913
AstraZeneca UKNone$12,089
11 payments
  • Consulting · 2022-09-06 · $537
  • Consulting · 2022-05-10 · $806
  • Meals · 2022-03-11 · $107
  • Meals · 2022-03-11 · $78
  • Travel · 2022-03-11 · $9,800
  • Meals · 2022-03-11 · $73
  • Travel · 2022-03-11 · $171
  • Travel · 2022-03-11 · $126
  • Travel · 2022-03-11 · $126
  • Travel · 2022-03-11 · $171
  • Meals · 2022-03-11 · $95
AstraZeneca Pharmaceuticals LPBreztri$4,565
2 payments
  • Consulting for Breztri · 2022-07-06 · $2,417
  • Consulting for Breztri · 2022-07-04 · $2,148
Gilead SciencesNone$157
3 payments
  • Meals · 2022-09-04 · $83
  • Meals · 2022-05-17 · $15
  • Meals · 2022-05-16 · $59

2021: $14,364

Payments by company in 2021
AstraZeneca Pharmaceuticals LPBreztri$7,589
7 payments
  • Paid to speak or teach · 2021-10-03 · $1,050
  • Consulting for Breztri · 2021-09-02 · $2,009
  • Consulting for Breztri · 2021-06-03 · $423
  • Paid to speak or teach · 2021-05-12 · $300
  • Consulting for Breztri · 2021-04-22 · $846
  • Consulting for Breztri · 2021-04-19 · $1,269
  • Consulting for Breztri · 2021-01-06 · $1,692
GenzymeDupixent$5,475
1 payment
  • Consulting for Dupixent · 2021-12-01 · $5,475
GlaxoSmithKlineTrelegy Ellipta$1,300
1 payment
  • Consulting for Trelegy Ellipta · 2021-05-11 · $1,300

2020: $58,717

Payments by company in 2020
Sunovion PharmaceuticalsNone$41,328
2 payments
  • Consulting · 2020-03-05 · $1,548
  • Consulting · 2020-02-27 · $39,780
GlaxoSmithKlineTrelegy Ellipta$7,025
6 payments
  • Consulting · 2020-12-08 · $650
  • Consulting · 2020-07-24 · $813
  • Consulting for Trelegy Ellipta · 2020-02-27 · $5,200
  • Travel for Trelegy Ellipta · 2020-01-16 · $230
  • Meals for Trelegy Ellipta · 2020-01-16 · $48
  • Meals for Trelegy Ellipta · 2020-01-16 · $84
AstraZeneca Pharmaceuticals LPBreztri Aerosphere$6,558
7 payments
  • Consulting for Breztri Aerosphere · 2020-12-10 · $423
  • Consulting for Breztri Aerosphere · 2020-10-08 · $1,058
  • Consulting for Fasenra · 2020-08-20 · $1,058
  • Consulting for Breztri Aerosphere · 2020-06-16 · $846
  • Consulting for Breztri Aerosphere · 2020-06-02 · $1,269
  • Consulting for Breztri Aerosphere · 2020-05-11 · $635
  • Consulting for Breztri Aerosphere · 2020-04-19 · $1,269
AstraZeneca UKNone$3,807
2 payments
  • Consulting · 2020-08-14 · $1,692
  • Consulting · 2020-01-14 · $2,115

2019: $44,753

Payments by company in 2019
AstraZeneca UKFasenra$17,954
14 payments
  • Travel · 2019-12-09 · $322
  • Travel · 2019-12-09 · $575
  • Meals · 2019-12-08 · $18
  • Meals · 2019-12-07 · $19
  • Meals · 2019-12-07 · $42
  • Meals · 2019-12-07 · $23
  • Meals · 2019-12-07 · $18
  • Meals · 2019-12-06 · $51
  • Travel · 2019-12-06 · $10,626
  • Meals · 2019-12-06 · $19
  • Consulting for Fasenra · 2019-08-01 · $423
  • Consulting for Fasenra · 2019-08-01 · $2,115
  • Consulting for Fasenra · 2019-03-21 · $3,067
  • Consulting for Fasenra · 2019-03-21 · $635
GlaxoSmithKlineAnoro$17,447
20 payments
  • Consulting for Anoro · 2019-07-24 · $7,800
  • Meals for Anoro · 2019-06-28 · $38
  • Meals for Anoro · 2019-06-28 · $14
  • Travel for Anoro · 2019-06-28 · $43
  • Meals for Anoro · 2019-06-28 · $35
  • Meals for Anoro · 2019-06-28 · $23
  • Meals for Anoro · 2019-06-27 · $120
  • Travel for Anoro · 2019-06-27 · $192
  • Travel for Anoro · 2019-06-27 · $93
  • Travel for Anoro · 2019-06-06 · $685
  • Consulting · 2019-05-24 · $7,150
  • Meals · 2019-05-03 · $33
  • Meals · 2019-05-03 · $77
  • Travel · 2019-05-03 · $86
  • Meals · 2019-05-03 · $70
  • Meals · 2019-05-03 · $14
  • Travel · 2019-05-02 · $200
  • Meals · 2019-05-02 · $60
  • Travel · 2019-05-01 · $211
  • Travel · 2019-04-16 · $503
AstraZeneca Pharmaceuticals LPFasenra$5,227
12 payments
  • Consulting for Fasenra · 2019-05-01 · $3,900
  • Travel for Fasenra · 2019-04-10 · $568
  • Meals for Fasenra · 2019-04-10 · $48
  • Travel for Fasenra · 2019-04-10 · $319
  • Meals for Fasenra · 2019-04-10 · $35
  • Meals for Fasenra · 2019-04-10 · $19
  • Meals for Fasenra · 2019-04-10 · $28
  • Meals · 2019-02-24 · $50
  • Meals · 2019-02-24 · $40
  • Meals · 2019-02-24 · $67
  • Meals · 2019-02-20 · $94
  • Meals · 2019-02-12 · $59
AmgenParsabiv$4,125
1 payment
  • Consulting for Parsabiv · 2019-02-04 · $4,125

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
GENZYME CORPORATION · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Pivotal Study To Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (Copd) With Type 2 Inflammation · 2024This clinician$14,000
GENZYME CORPORATION · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Pivotal Study To Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (Copd) With Type 2 Inflammation · 2025This clinician$5,000
GENZYME CORPORATION · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Pivotal Study To Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (Copd) With Type 2 Inflammation · 2024This clinician$4,250
GENZYME CORPORATION · Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess the Efficacy, Safety, and Tolerability of Sar231893/Regn668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate To Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled By Inhaled Corticosteroid Plus Long-Acting Beta2 Agonist Therapy · 2025This clinician$2,000
GENZYME CORPORATION · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept (Poc) Study To Assess the Efficacy, Safety and Tolerability of Sar440340, in Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (Copd) · 2024This clinician$1,250
F. Hoffmann-La Roche AG · A Phase Iib, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study To Assess the Efficacy and Safety of Mstt1041a in Patients With Uncontrolled Severe Asthma, Anti-St2 Copd Iss Ph2a · 2025This clinician$951
GENZYME CORPORATION · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Pivotal Study To Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (Copd) With Type 2 Inflammation · 2023This clinician$750
GENZYME CORPORATION · Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess the Efficacy, Safety, and Tolerability of Sar231893/Regn668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate To Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled By Inhaled Corticosteroid Plus Long-Acting Beta2 Agonist Therapy · 2024This clinician$500

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
74.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1528234937
Licence
CA A112221California A112221: Current · expires 2028-05-31
Trained
Medical College of Wisconsin, 2006 · 20 years ago
Group
University of California San Francisco · Regents of the University of California
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Internal medicine (207R00000X)
Mailing address
275 W Macarthur, Oakland, CA, 94611
NPI first listed
2008-05-06
NPI last updated
2014-11-04

This is when the NPI record was last certified, not a medical board exam.